Prospective, randomized, open-label phase ii trial on concomitant intraventricular fibrinolysis and low-frequency rotation after severe subarachnoid hemorrhage

Stroke

Volumn 44, Issue 8, 2013, Pages 2162-2168

  Etminan, Nima ^a   Beseoglu, Kerim ^a   Eicker, Sven Oliver ^a   Turowski, Bernd ^b   Steiger, Hans Jakob ^a   Hänggi, Daniel ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Department of Orthopedic Surgery   (Germany)

Author keywords

concomitant fibrinolysis and kinetic therapy; radiographic vasospasm; subarachnoid hemorrhage

Indexed keywords

ALTEPLASE; MIDAZOLAM; NIMODIPINE; PROPOFOL; SUFENTANIL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BRAIN ISCHEMIA; BRAIN RADIOGRAPHY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; GLASGOW OUTCOME SCALE; HEAD MOTION THERAPY; HEMATOMA; HOSPITAL DISCHARGE; HUMAN; HYDROCEPHALUS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOVEMENT THERAPY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBARACHNOID HEMORRHAGE;

CONCOMITANT FIBRINOLYSIS AND KINETIC THERAPY; RADIOGRAPHIC VASOSPASM; SUBARACHNOID HEMORRHAGE;

AGED; CEREBRAL VENTRICLES; ENDOVASCULAR PROCEDURES; EXERCISE THERAPY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEAD; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROTATION; SEVERITY OF ILLNESS INDEX; SUBARACHNOID HEMORRHAGE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84880791690     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001790     Document Type: Article

References (27)

1. Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of sub-arachnoid hemorrhage: Population-based study and systematic review. Neurology. 2010;74:1494-1501.
2. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al.; CONSCIOUS-1 Investigators. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-fnding trial. Stroke. 2008;39:3015-3021.
3. Findlay JM. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery. 1995;37:1026-1027.
4. Sasaki T, Kodama N, Kawakami M, Sato M, Asari J, Sakurai Y, et al. Urokinase cisternal irrigation therapy for prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: a study of urokinase concentration and the fbrinolytic system. Stroke. 2000;31:1256-1262. (Pubitemid 30351242)
5. Seifert V, Stolke D, Zimmermann M, Feldges A. Prevention of delayed ischaemic defcits after aneurysmal subarachnoid haemorrhage by intra-thecal bolus injection of tissue plasminogen activator (rTPA). A prospective study. Acta Neurochir (Wien). 1994;128:137-143. (Pubitemid 24208554)
6. Yamamoto T, Esaki T, Nakao Y, Mori K. Effcacy of low-dose tissue-plasminogen activator intracisternal administration for the prevention of cerebral vasospasm after subarachnoid hemorrhage. World Neurosurg. 2010;73:675-682.
7. Kawamoto S, Tsutsumi K, Yoshikawa G, Shinozaki MH, Yako K, Nagata K, et al. Effectiveness of the head-shaking method combined with cis-ternal irrigation with urokinase in preventing cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 2004;100:236-243. (Pubitemid 38140226)
8. Report of world federation of neurological surgeons committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg. 1988;68:985-986
9. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to sub-arachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1-9. (Pubitemid 10159923)
10. Etminan N, Beseoglu K, Heiroth HJ, Turowski B, Steiger HJ, Hanggi D. Early perfusion computerized tomography imaging as a radiographic surrogate for delayed cerebral ischemia and functional outcome after subarachnoid hemorrhage. Stroke. 2013;44:1260-1266.
11. Hänggi D, Liersch J, Turowski B, Yong M, Steiger HJ. The effect of lumboventricular lavage and simultaneous low-frequency head-motion therapy after severe subarachnoid hemorrhage: results of a single center prospective Phase II trial. J Neurosurg. 2008;108:1192-1199. (Pubitemid 351798496)
12. Wintermark M, Ko NU, Smith WS, Liu S, Higashida RT, Dillon WP. Vasospasm after subarachnoid hemorrhage: utility of perfusion CT and CT angiography on diagnosis and management. Am J Neuroradiol. 2006;27:26-34. (Pubitemid 46939879)
13. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar J P, et al. Defnition of delayed cerebral ischemia after aneu-rysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41:2391-2395.
14. Hänggi D, Eicker S, Beseoglu K, Behr J, Turowski B, Steiger HJ. A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm. Cent Eur Neurosurg. 2009;70:61-67.
15. Amin-Hanjani S, Ogilvy CS, Barker FG 2nd. Does intracisternal throm-bolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery. 2004;54:326-334; discussion 334.
16. Eicker SO, Beseoglu K, Etminan N, Perrin J, Taskin A, Steiger HJ, et al. The effect of intraventricular thrombolysis in combination with low-frequency head motion after severe subarachnoid hemorrhage: interim analysis of safety, clot clearance rate and delayed cerebral ischemia. Acta Neurochir Suppl. 2012;114:323-328.
17. Ramakrishna R, Sekhar LN, Ramanathan D, Temkin N, Hallam D, Ghodke B V, et al. Intraventricular tissue plasminogen activator for the prevention of vasospasm and hydrocephalus after aneurysmal subarach-noid hemorrhage. Neurosurgery. 2010;67:110-117; discussion 117.
18. Cho E, Lee KJ, Seo JW, Byun CJ, Chung SJ, Suh DC, et al. Neuroprotection by urokinase plasminogen activator in the hippocampus. Neurobiol Dis. 2012;46:215-224.
19. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature. 1996;384:123-124.
20. Staykov D, Wagner I, Volbers B, Huttner HB, Doerfer A, Schwab S, et al. Dose effect of intraventricular fbrinolysis in ventricular hemorrhage. Stroke. 2011;42:2061-2064.
21. Vergouwen MD, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and-independent effects. Stroke. 2011;42:924-929.
22. Cahill J, Zhang JH. Subarachnoid hemorrhage: is it time for a new direction? Stroke. 2009;40(suppl 3):S86-S87.
23. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after sub-arachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol. 2007;3:256-263. (Pubitemid 46745473)
24. Fergusen S, Macdonald RL. Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery. 2007;60:658-667; discussion 667.
25. Kreiter KT, Mayer SA, Howard G, Knappertz V, Ilodigwe D, Sloan MA, et al. Sample size estimates for clinical trials of vasospasm in subarach-noid hemorrhage. Stroke. 2009;40:2362-2367.
26. Etminan N, Vergouwen MDI, Macdonald RL. Angiographic vasospasm versus cerebral infarction as outcome measures after subarachnoid hemorrhage. Acta Neurochir Suppl (Wien). 2013;115:33-40
27. Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2011;31:1545-1553.